At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Brequinar +1 moredrug
Likely dose
Brequinar 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19)
In Brief
A Phase 2 clinical trial evaluating Brequinar and Standard of Care for COVID-19. Completed, enrolled 25 participants across 5 sites.
Detailed Summary
This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartAug 2020
Primary CompletionDec 2020
Study CompletionJan 2021
TodayJul 2026
First PostedJun 11, 2020
Enrollment StartAug 19, 2020
Primary CompletionDec 29, 2020
Study CompletionJan 12, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.1 years ago
Interventions
Brequinardrug
DHODH inhibitor, 100 mg daily x 5 days
Standard of Careother
Standard of Care per institutional guidelines for COVID-19 patients